Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

References

• Agusti A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev. 2019;28(154):190095. doi:10.1183/16000617.0095-2019
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi:10.1016/j.coph.2020.11.003
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther. 2006;318(2):840–848. doi:10.1124/jpet.105.099192
   PubMed Web of Science ®Google Scholar
• Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol. 2014;114(5):365–376. doi:10.1111/bcpt.12209
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694. doi:10.1016/S0140-6736(09)61255-1
   PubMed Web of Science ®Google Scholar
• Dransfield M, Rowe S, Vogelmeier CF, et al. Cystic Fibrosis Transmembrane Conductance Regulator: roles in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2022;205(6):631–640. doi:10.1164/rccm.202109-2064TR
   PubMed Web of Science ®Google Scholar
• Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157(6):892–906. doi:10.1111/j.1476-5381.2009.00170.x
   PubMed Web of Science ®Google Scholar
• Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019;197:225–242. doi:10.1016/j.pharmthera.2019.02.002
   PubMed Web of Science ®Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414–423. doi:10.1124/jpet.113.204644
   PubMed Web of Science ®Google Scholar
• Turner MJ, Matthes E, Billet A, et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2016;310(1):L59–70. doi:10.1152/ajplung.00324.2015
   PubMed Web of Science ®Google Scholar
• Turner MJ, Dauletbaev N, Lands LC, Hanrahan JW. The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4. J Pharmacol Exp Ther. 2020;375(3):414–429. doi:10.1124/jpet.120.000080
   PubMed Web of Science ®Google Scholar
• Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol Ther. 2021;224:107826. doi:10.1016/j.pharmthera.2021.107826
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23. doi:10.1016/j.pupt.2015.03.007
   PubMed Web of Science ®Google Scholar
• Keir S, Page C. RPL554, a dual phosphodiesterase (PDE) 3/4 inhibitor acts synergistically with muscarinic receptor antagonists and beta-adrenoceptor agonists to produce bronchodilation in vivo. C32 ASTHMA: PRE-CLINICAL STUDIES. Am Thorac Soc. 2014;A4218–A4218.
   Google Scholar
• Rheault T, MacDonald-Berko M. Antiinflammatory pharmacology of ensifentrine. Chest. 2020;158(4):A2284. doi:10.1016/j.chest.2020.08.1936
   Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi:10.1016/S2213-2600(13)70187-5
   PubMed Web of Science ®Google Scholar
• Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020;21(1):47. doi:10.1186/s12931-020-1307-4
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-2018
   PubMed Web of Science ®Google Scholar
• Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406–416. doi:10.1164/rccm.202306-0944OC
   PubMed Web of Science ®Google Scholar
• Rickard K, Darpo B, Xue H, Bengtsson T, Rheault T. The Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor Ensifentrine Does Not Prolong QT Interval in Healthy Volunteers. B39 COPD MANAGEMENT: FROM PHARMACOLOGIC TREATMENT TO NOVEL THERAPIES. Am Thorac Soc. 2022;A5605–A5605.
   Google Scholar
• Rickard K, Bengtsson T, Rheault T. Cardiovascular Safety Profile of Ensifentrine in Patients with COPD: results from Two Four-Week, Dose-Ranging, Randomized, Placebo-Controlled Trials. TP40 TP040 COPD CLINICAL TRIALS AND THERAPIES. Am Thorac Soc. 2021;A2256–A2256.
   Google Scholar
• Terry PD, Dhand R. Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. Adv Ther. 2020;37(5):1812–1828. doi:10.1007/s12325-020-01289-y
   PubMed Web of Science ®Google Scholar
• Martin C, Burgel PR, Roche N. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: a Short Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2363–2373. doi:10.2147/COPD.S226688
   PubMed Web of Science ®Google Scholar
• Drugs.com. Ensifentrine FDA Approval Status. Available from: https://www.drugs.com/history/ensifentrine.html. Accessed October 30, 2023.
   Google Scholar